Interaction Matrix

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

1 hit, a review of anti-acne agents that mentions afamelanotide in passing; not an interaction study.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

PubMed

• digoxin, warfarin, a low-dose oral contraceptive (norethindrone with ethinyl estradiol): no clinically significant pharmacokinetic or pharmacodynamic interaction in three phase 1 studies in healthy volunteers; warfarin's INR unaffectedBush, M. et al. (2012). Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgraduate Medicine, 124(6), 55-72. PubMed
• drugs studied in its clinical programme: no clinically relevant drug interactions observed (review by the manufacturer's clinical pharmacologists)Young, M. A. et al. (2014). Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgraduate Medicine, 126(7), 84-97. PubMed

Albiglutide was discontinued by its maker; the studies date from its development.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Anamorelin is approved in Japan as Adlumiz; its Japanese label was not read for this record, so any interactions it lists are not reflected here.

FDA label, section 7

• ACE inhibitors: may increase the response to angiotensin IIGiapreza (angiotensin II) injection, US prescribing information, section 7. DailyMed version 18, effective July 22, 2026, read September 30, 2026.
• angiotensin II receptor blockers: may decrease the response to angiotensin IIGiapreza (angiotensin II) injection, US prescribing information, section 7. DailyMed version 18, effective July 22, 2026, read September 30, 2026.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (23 hits read).

23 hits: intravenous Y-site compatibility studies, combined tocolysis experiments in isolated myometrium, and animal work. Compatibility in a line is not a pharmacological interaction, and no human interaction study was found.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (79 hits read).

79 hits, essentially all laboratory synergy testing against bacteria (bacitracin combined with other antibiotics or compounds in culture) or bacitracin used as a protease inhibitor in absorption experiments; none is a drug interaction study in people.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

The alias 'Benefit' was excluded from the search because as a common word it matched 3,513 unrelated papers; the name-only query returned none.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

FDA label, section 7

• heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors: increased risk of major bleeding when given together, seen in PCI trialsBivalirudin for injection (Avenacy), US prescribing information, section 7. DailyMed version 2, effective August 20, 2026, read September 30, 2026.

PubMed

• milrinone: studied together in decompensated heart failure; both lower filling pressures and the combination has been examined for additive hypotensionAronson D, Burger AJ. "Concomitant use of nesiritide and milrinone in decompensated congestive heart failure." Am J Health Syst Pharm. 2005;62(4):410-4. PMID: 15719588. PubMed
• heparin-coated pulmonary artery catheters: a reported physical interaction during infusion, which is a device interaction rather than a pharmacological oneDunlap SH, et al. "Interaction between nesiritide and a heparin-coated pulmonary artery line during an infusion for decompensated heart failure." Pharmacotherapy. 2004;24(12):1799-802. PMID: 15537565. PubMed

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (20 hits read).

20 hits: absorption-enhancer and drug-delivery experiments using buserelin as a model peptide, animal work, and trials of other drugs given in GnRH agonist protocols. No human interaction study of buserelin itself.

PubMed

• semaglutide 2.4 mg: concomitant administration studied in a randomised phase 1b trial (96 participants) of safety, pharmacokinetics and pharmacodynamics; the combination is investigational as CagriSemaEnebo, L. B. et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet, 397, 1736-1748. PubMed

Found by a follow-up search for concomitant administration (the template query does not include 'concomitant'). The template's six hits are rat studies, the REDEFINE 2 efficacy trial of the combination, and two unrelated pharmacokinetics papers.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

FDA label, section 7 (no formal interaction studies were performed)

• lithium: may lower plasma lithium by increasing its urinary clearance; the lithium dose may need adjustingMiacalcin (calcitonin salmon) injection, US prescribing information, section 7. DailyMed version 5, effective September 15, 2024, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Capromorelin is approved only as a veterinary drug (Entyce, Elura); no human interaction study is published.

No interaction study was found in a PubMed search on 2026-09-30 (4 hits read).

The four hits are animal behaviour studies and an in vitro enzyme study; no interaction study in people. Approved outside the US.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

PubMed

• acetaminophen (paracetamol): co-administration relieved neuropathic pain more than acetaminophen alone in rats with nerve injury; animal workOwoyele BV, et al. "Synergistic interaction between acetaminophen and L-carnosine improved neuropathic pain via NF-κB pathway and antioxidant properties in chronic constriction injury model." Korean J Pain, 2022;35(3):271-279. PMID: 35768982. PubMed
• 5-fluorouracil: in colon cancer cells it overcame acquired resistance to 5-fluorouracil; laboratory workIovine B, et al. "l-carnosine dipeptide overcomes acquired resistance to 5-fluorouracil in HT29 human colon cancer cells via downregulation of HIF1-alpha and induction of apoptosis." Biochimie, 2016;127:196-204. PMID: 27234614. PubMed

Most of the 37 hits are animal or cell combinations; no interaction study in people was found.

No interaction study was found in a PubMed search on 2026-09-30 (5 hits read).

The five hits are in vitro and animal studies (for example, human bronchial rings in vitro, 1994); no interaction study in people. Approved in Japan.

No interaction study was found in a PubMed search on 2026-09-30 (2 hits read).

The two hits are unrelated (a breast-cancer genomics paper and a heparin cofactor peptide).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (16 hits read).

No interaction study in people. The co-administration hits are rodent neuroprotection experiments combining it with stem cells, antibodies or nanowired delivery, one of which has been retracted; a 2020 Russian clinical paper discusses combining neuroprotective regimens without measuring an interaction.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, Drug Interactions

• aminoglycosides and polymyxins: also interfere with neuromuscular transmission; give together only with the greatest cautionColy-Mycin M Parenteral (colistimethate sodium) for injection, US prescribing information, Drug Interactions. DailyMed version 27, effective June 8, 2026, read September 30, 2026.
• curariform muscle relaxants such as tubocurarine, and ether, succinylcholine, gallamine, decamethonium and sodium citrate: potentiate neuromuscular blockade; use with extreme cautionColy-Mycin M Parenteral (colistimethate sodium) for injection, US prescribing information, Drug Interactions. DailyMed version 27, effective June 8, 2026, read September 30, 2026.
• sodium cephalothin: may increase kidney toxicity; the label says to avoid using them togetherColy-Mycin M Parenteral (colistimethate sodium) for injection, US prescribing information, Drug Interactions. DailyMed version 27, effective June 8, 2026, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

The single hit tests a milk-ceramide and collagen-peptide mixture against UV damage in cells and mice, a supplement combination rather than a drug interaction.

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

The single hit is a rat hippocampal culture study of amyloid-beta toxicity, not an interaction.

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

The one hit is an unrelated fusion-protein construct paper. Approved in the EU (Elonva); its EU product information is not yet part of this review.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (2 hits read).

Hits are a Russian review of drug synergism in neuroprotection and a 1988 animal study of transplacental carcinogenesis; no human interaction study.

FDA label, precautions (drug interactions)

• dexamethasone pretreatment: inhibits or blunts the plasma ACTH response to corticorelinFerring. ACTHREL (corticorelin ovine triflutate for injection), US prescribing information, Precautions: Drug Interactions. DailyMed version of November 12, 2021, read September 30, 2026.
• heparin (to keep an intravenous cannula open): not recommended during the test; a possible interaction may explain a major hypotensive reaction after corticorelinFerring. ACTHREL (corticorelin ovine triflutate for injection), US prescribing information, Precautions: Drug Interactions. DailyMed version of November 12, 2021, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

The single hit is a receptor-pharmacology paper on biased agonism at the GLP-1 and glucagon receptors, not an interaction study.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

FDA label, section 7

• HMG-CoA reductase inhibitors (statins): experience together is limited and some patients on both had raised creatine phosphokinase; consider suspending the statin during treatmentCubicin RF (daptomycin) for injection, US prescribing information, section 7. DailyMed version 22, effective March 17, 2025, read September 30, 2026.
• recombinant thromboplastin reagents used for prothrombin time and INR: a laboratory interaction that falsely prolongs PT and raises INR; draw the sample near the trough and consider another methodCubicin RF (daptomycin) for injection, US prescribing information, section 7. DailyMed version 22, effective March 17, 2025, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (3 hits read).

Hits are a rat epilepsy study, a study of NAP analogues and a development review; the alias 'NAP' was excluded as a common word.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, precautions (drug interactions)

• other pressor agents: large doses should be used with other pressor agents only with careful monitoringFerring Pharmaceuticals. DDAVP (desmopressin acetate) tablets, US prescribing information, Precautions: Drug Interactions. DailyMed version of December 10, 2025, read September 30, 2026.
• drugs that raise the risk of water intoxication with hyponatraemia (tricyclic antidepressants, SSRIs, chlorpromazine, opiate analgesics, NSAIDs, lamotrigine, carbamazepine): use together with cautionFerring Pharmaceuticals. DDAVP (desmopressin acetate) tablets, US prescribing information, Precautions: Drug Interactions. DailyMed version of December 10, 2025, read September 30, 2026.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, section 7

• oral medicines, especially those with a narrow therapeutic index such as warfarin: delays stomach emptying and can slow their absorption; monitor drug levelsTrulicity (dulaglutide) injection, US prescribing information, section 7. DailyMed version 62, effective June 16, 2026, read September 30, 2026.
• insulin secretagogues such as sulfonylureas, or insulin: raises the risk of low blood sugar; consider reducing their dose when startingTrulicity (dulaglutide) injection, US prescribing information, section 7. DailyMed version 62, effective June 16, 2026, read September 30, 2026.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

FDA label, section 7

• digoxin: raises digoxin levels; monitor more closely when starting or stopping elagolixOrilissa (elagolix) tablets, US prescribing information, section 7. DailyMed version 112, effective December 19, 2025, read September 30, 2026.
• oral midazolam: lowers midazolam levels; consider up to a two-fold dose increase, individualisedOrilissa (elagolix) tablets, US prescribing information, section 7. DailyMed version 112, effective December 19, 2025, read September 30, 2026.
• rosuvastatin: lowers rosuvastatin levels; monitor lipids and adjust if neededOrilissa (elagolix) tablets, US prescribing information, section 7. DailyMed version 112, effective December 19, 2025, read September 30, 2026.
• omeprazole: raises omeprazole levels; consider a lower omeprazole dose at higher dosesOrilissa (elagolix) tablets, US prescribing information, section 7. DailyMed version 112, effective December 19, 2025, read September 30, 2026.
• combined hormonal contraceptives: raises ethinyl estradiol and lowers levonorgestrel; use effective non-hormonal contraception during treatment and for 28 days afterOrilissa (elagolix) tablets, US prescribing information, section 7. DailyMed version 112, effective December 19, 2025, read September 30, 2026.
• strong CYP3A inhibitors: raise elagolix levels; concomitant use with 200 mg twice daily beyond 1 month is not recommended, and with 150 mg once daily is limited to 6 monthsOrilissa (elagolix) tablets, US prescribing information, section 7. DailyMed version 112, effective December 19, 2025, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, section 7

• antiplatelet agents, thrombolytics, heparin, aspirin and chronic NSAID use: coadministration increases the risk of bleedingAvenacy. Eptifibatide injection, US prescribing information, section 7.1. DailyMed version of August 15, 2024, read September 30, 2026.
• other glycoprotein IIb/IIIa inhibitors: avoid concomitant useAvenacy. Eptifibatide injection, US prescribing information, section 7.1. DailyMed version of August 15, 2024, read September 30, 2026.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, section 7

• warfarin: postmarketing reports of a raised INR, sometimes with bleeding; monitor prothrombin time more often after starting or changing the doseByetta (exenatide) injection, US prescribing information, section 7. DailyMed version 26, effective September 2, 2025, read September 30, 2026.
• oral medicines that depend on reaching a threshold concentration, such as contraceptives and antibiotics: slowed stomach emptying can reduce their absorption; take them at least 1 hour before the injectionByetta (exenatide) injection, US prescribing information, section 7. DailyMed version 26, effective September 2, 2025, read September 30, 2026.
• insulin secretagogues such as sulfonylureas, or insulin: raises the risk of low blood sugar; consider reducing their dose when startingByetta (exenatide) injection, US prescribing information, section 7. DailyMed version 26, effective September 2, 2025, read September 30, 2026.

PubMed

• tricyclic antidepressants: a 1979 study examined the safety of prilocaine with felypressin in patients taking tricyclics, the group in whom adrenaline-containing anaesthetics are a concernPerovic J, et al. "Safety of local anaesthesia induced by prilocaine with felypressin in patients on tricyclic antidepressants." Bull Group Int Rech Sci Stomatol Odontol, 1979;22(2):57-62. PMID: 294301. PubMed
• cocaine: a 1985 case report describes severe hypertension and ST depression after intranasal cocaine followed by felypressin injection, and suspected a drug interactionel-Din AS, et al. "Severe hypertension during anaesthesia for dacryocystorhinostomy." Anaesthesia, 1985;40(8):787-9. PMID: 4037272. PubMed
• halothane anaesthesia: during nasal surgery under halothane, prilocaine with felypressin caused significantly fewer cardiac dysrhythmias than lignocaine with adrenaline, with somewhat less complete haemostasisElhakim M, et al. "Cardiac dysrhythmias during nasal surgery--a comparison with lignocaine-adrenaline and prilocaine-octapressin during halothane anaesthesia." Anaesthesiol Reanim, 1990;15(4):199-203. PMID: 2222714. PubMed

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (2 hits read).

2 hits, neither an interaction study: a within-patient rescue-protocol comparison and a review of personalised dosing.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, Drug Interactions (which states that no formal studies were performed)

• any drug: the label records that no formal drug interaction studies have been performedGanirelix acetate injection, US prescribing information, Drug Interactions. DailyMed version 2, effective May 11, 2026, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

PubMed

• liraglutide: pharmacological GDF15 and liraglutide acted synergistically on food intake in mice; animal workFrikke-Schmidt H, et al. "GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice." Mol Metab, 2019;21:13-21. PMID: 30685336. PubMed

The other hits concern GDF15 as a biomarker or signalling molecule, not GDF15 given as a drug.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (18 hits read).

18 hits: combination-therapy studies of glatiramer with interferon beta in multiple sclerosis (a treatment combination, not a pharmacokinetic interaction), animal models, and reviews of other MS drugs. No human drug interaction study of glatiramer.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (48 hits read).

48 hits, essentially all laboratory synergy testing against bacteria or gramicidin used as an ionophore tool in electrophysiology; none is a drug interaction study in people.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (3 hits read).

Hits are in vitro studies (antimicrobial peptides with antibiotics against Clostridium difficile; Caco-2 cells) and an unrelated ketoconazole formulation paper; no human interaction study.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, section 7 (no formal drug-drug, drug-food or drug-herb studies were performed; the interactions recorded are with laboratory tests)

• diagnostic tests of pituitary and gonadal function: suppression of the pituitary-gonadal system can affect results during and after treatmentSupprelin LA (histrelin acetate) subcutaneous implant, US prescribing information, section 7. DailyMed version 38, effective September 25, 2025, read September 30, 2026.
• laboratory IGF-1 and DHEA measurements: mean IGF-1 fell about 11% in one study and DHEA rose in 8 of 36 patients in anotherSupprelin LA (histrelin acetate) subcutaneous implant, US prescribing information, section 7. DailyMed version 38, effective September 25, 2025, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

FDA label, section 7

• ACE inhibitors: as a bradykinin B2 receptor antagonist, icatibant may blunt their blood-pressure-lowering effect; its trials excluded people taking themFirazyr (icatibant) injection, US prescribing information, section 7. DailyMed version 19, effective July 7, 2025, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

1 hit, a 2026 review of icotrokinra for psoriasis; not an interaction study.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

FDA label, section 7

• drugs that may increase the risk of hypoglycaemia (other antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues such as octreotide, sulfonamide antibiotics): dose adjustment and more frequent glucose monitoring may be neededNovo Nordisk. NOVOLOG (insulin aspart) injection, US prescribing information, section 7, Table: clinically significant drug interactions. DailyMed version of January 22, 2025, read September 30, 2026.
• drugs that may decrease the glucose-lowering effect (atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics, thyroid hormones): dose adjustment and more frequent glucose monitoring may be neededNovo Nordisk. NOVOLOG (insulin aspart) injection, US prescribing information, section 7, Table: clinically significant drug interactions. DailyMed version of January 22, 2025, read September 30, 2026.
• alcohol, beta-blockers, clonidine, lithium salts: may increase or decrease the glucose-lowering effectNovo Nordisk. NOVOLOG (insulin aspart) injection, US prescribing information, section 7, Table: clinically significant drug interactions. DailyMed version of January 22, 2025, read September 30, 2026.

FDA label, section 7

• drugs that raise the risk of low blood sugar (other diabetes drugs, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues such as octreotide, sulfonamide antibiotics): dose reduction and more frequent glucose monitoring may be neededTresiba (insulin degludec) injection, US prescribing information, section 7. DailyMed version 14, effective July 1, 2022, read September 30, 2026.
• drugs that weaken its glucose-lowering effect (atypical antipsychotics, corticosteroids, danazol, diuretics, oestrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics such as albuterol, epinephrine and terbutaline, thyroid hormones): dose increases and more frequent glucose monitoring may be neededTresiba (insulin degludec) injection, US prescribing information, section 7. DailyMed version 14, effective July 1, 2022, read September 30, 2026.
• alcohol, beta-blockers, clonidine and lithium salts: may raise or lower the glucose-lowering effect; pentamidine may cause low blood sugar sometimes followed by high blood sugarTresiba (insulin degludec) injection, US prescribing information, section 7. DailyMed version 14, effective July 1, 2022, read September 30, 2026.
• beta-blockers, clonidine, guanethidine and reserpine: may blunt or hide the warning signs of low blood sugarTresiba (insulin degludec) injection, US prescribing information, section 7. DailyMed version 14, effective July 1, 2022, read September 30, 2026.

FDA label, section 7

• drugs that raise the risk of low blood sugar (other diabetes drugs, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues such as octreotide, sulfonamide antibiotics): dose reduction and more frequent glucose monitoring may be neededXultophy 100/3.6 (insulin degludec and liraglutide) injection, US prescribing information, section 7. DailyMed version 14, effective October 14, 2025, read September 30, 2026.
• drugs that weaken its glucose-lowering effect (atypical antipsychotics, corticosteroids, danazol, diuretics, oestrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics such as albuterol, epinephrine and terbutaline, thyroid hormones): dose increases and more frequent glucose monitoring may be neededXultophy 100/3.6 (insulin degludec and liraglutide) injection, US prescribing information, section 7. DailyMed version 14, effective October 14, 2025, read September 30, 2026.
• alcohol, beta-blockers, clonidine and lithium salts: may raise or lower the glucose-lowering effect; pentamidine may cause low blood sugar sometimes followed by high blood sugarXultophy 100/3.6 (insulin degludec and liraglutide) injection, US prescribing information, section 7. DailyMed version 14, effective October 14, 2025, read September 30, 2026.
• beta-blockers, clonidine, guanethidine and reserpine: may blunt or hide the warning signs of low blood sugarXultophy 100/3.6 (insulin degludec and liraglutide) injection, US prescribing information, section 7. DailyMed version 14, effective October 14, 2025, read September 30, 2026.
• oral medicines: the liraglutide component delays stomach emptying, which may affect their absorptionXultophy 100/3.6 (insulin degludec and liraglutide) injection, US prescribing information, section 7. DailyMed version 14, effective October 14, 2025, read September 30, 2026.

FDA label, drug interactions subsection

• drugs that lower the blood-glucose-lowering effect (corticosteroids, danazol, diuretics, sympathomimetics such as epinephrine, albuterol and terbutaline, isoniazid, phenothiazines, somatropin, thyroid hormones, estrogens and progestogens): insulin dose adjustment and closer monitoring may be neededLevemir (insulin detemir) injection, US prescribing information, Precautions: Drug Interactions. DailyMed version 1, effective September 14, 2011 — the only Levemir label DailyMed still carries, distributed by a repackager; read September 30, 2026.
• drugs that raise the risk of low blood sugar (oral antidiabetic drugs, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, octreotide, sulfonamide antibiotics): hypoglycaemia risk rises; dose adjustment may be neededLevemir (insulin detemir) injection, US prescribing information, Precautions: Drug Interactions. DailyMed version 1, effective September 14, 2011 — the only Levemir label DailyMed still carries, distributed by a repackager; read September 30, 2026.
• beta-blockers, clonidine, lithium and alcohol: may strengthen or weaken the glucose-lowering effect; beta-blockers, clonidine, guanethidine and reserpine can also mask the warning signs of hypoglycaemiaLevemir (insulin detemir) injection, US prescribing information, Precautions: Drug Interactions. DailyMed version 1, effective September 14, 2011 — the only Levemir label DailyMed still carries, distributed by a repackager; read September 30, 2026.
• pentamidine: may cause hypoglycaemia, sometimes followed by hyperglycaemiaLevemir (insulin detemir) injection, US prescribing information, Precautions: Drug Interactions. DailyMed version 1, effective September 14, 2011 — the only Levemir label DailyMed still carries, distributed by a repackager; read September 30, 2026.

Levemir has been discontinued in the US; the label text is the manufacturer's, as carried by the one remaining DailyMed listing. It also states no clinically relevant interaction with fatty acids or other protein-bound drugs.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

FDA label, section 7

• drugs that raise the risk of low blood sugar (other diabetes drugs, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues such as octreotide, sulfonamide antibiotics): dose reduction and more frequent glucose monitoring may be neededLantus (insulin glargine) injection, US prescribing information, section 7. DailyMed version 35, effective June 2, 2025, read September 30, 2026.
• drugs that weaken its glucose-lowering effect (atypical antipsychotics, corticosteroids, danazol, diuretics, oestrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics such as albuterol, epinephrine and terbutaline, thyroid hormones): dose increases and more frequent glucose monitoring may be neededLantus (insulin glargine) injection, US prescribing information, section 7. DailyMed version 35, effective June 2, 2025, read September 30, 2026.
• alcohol, beta-blockers, clonidine and lithium salts: may raise or lower the glucose-lowering effect; pentamidine may cause low blood sugar sometimes followed by high blood sugarLantus (insulin glargine) injection, US prescribing information, section 7. DailyMed version 35, effective June 2, 2025, read September 30, 2026.
• beta-blockers, clonidine, guanethidine and reserpine: may blunt or hide the warning signs of low blood sugarLantus (insulin glargine) injection, US prescribing information, section 7. DailyMed version 35, effective June 2, 2025, read September 30, 2026.

FDA label, section 7

• drugs that affect glucose metabolism: dose adjustment may be needed; monitor blood glucose closelySanofi-Aventis U.S. SOLIQUA 100/33 (insulin glargine and lixisenatide injection), US prescribing information, section 7. DailyMed version effective March 18, 2026, read September 30, 2026.
• antiadrenergic drugs (beta-blockers, clonidine, guanethidine, reserpine): signs and symptoms of hypoglycaemia may be reducedSanofi-Aventis U.S. SOLIQUA 100/33 (insulin glargine and lixisenatide injection), US prescribing information, section 7. DailyMed version effective March 18, 2026, read September 30, 2026.
• oral medications, including oral contraceptives, antibiotics and acetaminophen: lixisenatide delays gastric emptying; take them at least 1 hour before or 11 hours after the injectionSanofi-Aventis U.S. SOLIQUA 100/33 (insulin glargine and lixisenatide injection), US prescribing information, section 7. DailyMed version effective March 18, 2026, read September 30, 2026.

FDA label, section 7

• drugs that raise the risk of low blood sugar (other diabetes drugs, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues such as octreotide, sulfonamide antibiotics): dose reduction and more frequent glucose monitoring may be neededApidra (insulin glulisine) injection, US prescribing information, section 7. DailyMed version 28, effective November 25, 2025, read September 30, 2026.
• drugs that weaken its glucose-lowering effect (atypical antipsychotics, corticosteroids, danazol, diuretics, oestrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics such as albuterol, epinephrine and terbutaline, thyroid hormones): dose increases and more frequent glucose monitoring may be neededApidra (insulin glulisine) injection, US prescribing information, section 7. DailyMed version 28, effective November 25, 2025, read September 30, 2026.
• alcohol, beta-blockers, clonidine and lithium salts: may raise or lower the glucose-lowering effect; pentamidine may cause low blood sugar sometimes followed by high blood sugarApidra (insulin glulisine) injection, US prescribing information, section 7. DailyMed version 28, effective November 25, 2025, read September 30, 2026.
• beta-blockers, clonidine, guanethidine and reserpine: may blunt or hide the warning signs of low blood sugarApidra (insulin glulisine) injection, US prescribing information, section 7. DailyMed version 28, effective November 25, 2025, read September 30, 2026.

FDA label, section 7

• drugs that raise the risk of low blood sugar (other diabetes drugs, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues such as octreotide, sulfonamide antibiotics): dose reduction and more frequent glucose monitoring may be neededAwiqli (insulin icodec) injection, US prescribing information, section 7. DailyMed version 1, effective March 26, 2026, read September 30, 2026.
• drugs that weaken its glucose-lowering effect (atypical antipsychotics, corticosteroids, danazol, diuretics, oestrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics such as albuterol, epinephrine and terbutaline, thyroid hormones): dose increases and more frequent glucose monitoring may be neededAwiqli (insulin icodec) injection, US prescribing information, section 7. DailyMed version 1, effective March 26, 2026, read September 30, 2026.
• alcohol, beta-blockers, clonidine and lithium salts: may raise or lower the glucose-lowering effect; pentamidine may cause low blood sugar sometimes followed by high blood sugarAwiqli (insulin icodec) injection, US prescribing information, section 7. DailyMed version 1, effective March 26, 2026, read September 30, 2026.
• beta-blockers, clonidine, guanethidine and reserpine: may blunt or hide the warning signs of low blood sugarAwiqli (insulin icodec) injection, US prescribing information, section 7. DailyMed version 1, effective March 26, 2026, read September 30, 2026.

FDA label, section 7

• drugs that raise the risk of low blood sugar (other diabetes drugs, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues such as octreotide, sulfonamide antibiotics): dose reduction and more frequent glucose monitoring may be neededHumalog (insulin lispro) injection, US prescribing information, section 7. DailyMed version 87, effective June 16, 2026, read September 30, 2026.
• drugs that weaken its glucose-lowering effect (atypical antipsychotics, corticosteroids, danazol, diuretics, oestrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics such as albuterol, epinephrine and terbutaline, thyroid hormones): dose increases and more frequent glucose monitoring may be neededHumalog (insulin lispro) injection, US prescribing information, section 7. DailyMed version 87, effective June 16, 2026, read September 30, 2026.
• alcohol, beta-blockers, clonidine and lithium salts: may raise or lower the glucose-lowering effect; pentamidine may cause low blood sugar sometimes followed by high blood sugarHumalog (insulin lispro) injection, US prescribing information, section 7. DailyMed version 87, effective June 16, 2026, read September 30, 2026.
• beta-blockers, clonidine, guanethidine and reserpine: may blunt or hide the warning signs of low blood sugarHumalog (insulin lispro) injection, US prescribing information, section 7. DailyMed version 87, effective June 16, 2026, read September 30, 2026.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

PubMed

• gonadotropin-inhibitory hormone (GnIH): in four men, an infusion of GnIH did not change the LH response to a kisspeptin-10 bolusGeorge JT, et al. "Effect of gonadotropin-inhibitory hormone on luteinizing hormone secretion in humans." Clin Endocrinol (Oxf), 2017;86(5):731-738. PMID: 28186349. PubMed
• oestrogen and progesterone: studied for their effect on kisspeptin-10's stimulation of LH and growth hormone in cows; animal workWhitlock BK, et al. "Interaction of estrogen and progesterone on kisspeptin-10-stimulated luteinizing hormone and growth hormone in ovariectomized cows." Neuroendocrinology, 2008;88(3):212-5. PMID: 18635924. PubMed
• methotrexate: given with methotrexate to rats to test protection against sperm damage; animal workGüvenç M, et al. "Ameliorating effect of kisspeptin-10 on methotrexate-induced sperm damages and testicular oxidative stress in rats." Andrologia, 2018;50(8):e13057. PMID: 29862548. PubMed

PubMed

• neurokinin B and naltrexone: co-administered to healthy men to test the KNDy hypothesis: every kisspeptin- and naltrexone-containing regimen potently increased LH and LH pulsatility against vehicleNarayanaswamy S, et al. "Investigating the KNDy Hypothesis in Humans by Coadministration of Kisspeptin, Neurokinin B, and Naltrexone in Men." J Clin Endocrinol Metab, 2016;101(9):3429-36. PMID: 27379743. PubMed

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Searched under langlenatide and efpeglenatide, the related Hanmi exendin conjugate; neither returned an interaction study.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (4 hits read).

All four hits are about a different compound that shares the code AT-1001, an alpha3beta4 nicotinic receptor ligand; none concerns larazotide.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

FDA label: no interactions section; the boxed warning and contraindication are an age limit, not a drug interaction

• no drug: the label carries no drug interactions section; linaclotide acts in the gut lumen and is minimally absorbedLinzess (linaclotide) capsules, US prescribing information, boxed warning and section 4. DailyMed version 39, effective May 21, 2026, read September 30, 2026.

The label's boxed warning contraindicates use under 2 years of age because neonatal mice died of dehydration at a clinically relevant adult dose. That is an age contraindication, not an interaction.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

PubMed

• oral medicines that need a target peak concentration or a rapid onset: GLP-1 receptor agonists lowered peak concentrations in 10 of the reviewed studies and delayed the time to peak in 14, so clinically meaningful interactions are possible; total exposure was equivalent in 11 of 15 interactions studiedHurren KM, Pinelli NR. "Drug-drug interactions with glucagon-like peptide-1 receptor agonists." Ann Pharmacother. 2012;46(5):710-7. PMID: 22510669. PubMed

Adlyxin has no current label on DailyMed (discontinued in the US), so this record rests on the published review of GLP-1 receptor agonist interactions, which searched lixisenatide by name.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study found; development stopped in 2022 before any label existed. Tolvaptan, the approved drug of its class, carries CYP3A interactions on its label, which were never characterised for lixivaptan.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, section 7

• glucocorticoid replacement, especially cortisone acetate and prednisone: growth hormone inhibits 11β-HSD-1 and can lower serum cortisol; maintenance or stress doses may need raisingSkytrofa (lonapegsomatropin-tcgd) for injection, US prescribing information, section 7. DailyMed version 13, effective July 23, 2026, read September 30, 2026.
• pharmacologic or supraphysiologic glucocorticoids: may blunt the growth-promoting effect in children; adjust replacement dosing carefullySkytrofa (lonapegsomatropin-tcgd) for injection, US prescribing information, section 7. DailyMed version 13, effective July 23, 2026, read September 30, 2026.
• drugs metabolised by cytochrome P450 enzymes: somatropin increases CYP450-mediated clearance; monitor carefullySkytrofa (lonapegsomatropin-tcgd) for injection, US prescribing information, section 7. DailyMed version 13, effective July 23, 2026, read September 30, 2026.
• oral oestrogen: may reduce the IGF-1 response; higher doses may be neededSkytrofa (lonapegsomatropin-tcgd) for injection, US prescribing information, section 7. DailyMed version 13, effective July 23, 2026, read September 30, 2026.
• insulin and other glucose-lowering drugs: may reduce insulin sensitivity, particularly at higher doses; diabetes treatment may need adjustingSkytrofa (lonapegsomatropin-tcgd) for injection, US prescribing information, section 7. DailyMed version 13, effective July 23, 2026, read September 30, 2026.

FDA label, section 7

• long-acting somatostatin analogues: compete for somatostatin receptors and may reduce efficacy; discontinue at least 4 weeks before each doseLutathera (lutetium Lu 177 dotatate) injection, US prescribing information, section 7. DailyMed version 12, effective January 15, 2026, read September 30, 2026.
• short-acting octreotide: same competition; discontinue at least 24 hours before each doseLutathera (lutetium Lu 177 dotatate) injection, US prescribing information, section 7. DailyMed version 12, effective January 15, 2026, read September 30, 2026.
• high-dose glucocorticoids: can down-regulate somatostatin receptor subtype 2; avoid repeated high doses during treatmentLutathera (lutetium Lu 177 dotatate) injection, US prescribing information, section 7. DailyMed version 12, effective January 15, 2026, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (2 hits read).

Both hits are efficacy trials in which lutropin alfa was given with follitropin alfa by design, the combination it is always used in; neither studies an interaction.

FDA label, section 7

• drugs that prolong the QT interval (antipsychotics, moxifloxacin, class IA and III antiarrhythmics): may lead to torsade de pointes; avoid together and allow a washout firstMacrilen (macimorelin) granules for oral solution, US prescribing information, section 7. DailyMed version 3, effective February 18, 2026, read September 30, 2026.
• strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St John's wort and others): lower macimorelin levels and may cause a false positive test; discontinue before the testMacrilen (macimorelin) granules for oral solution, US prescribing information, section 7. DailyMed version 3, effective February 18, 2026, read September 30, 2026.
• drugs affecting growth hormone release (somatostatin, insulin, glucocorticoids, aspirin and indomethacin; clonidine and levodopa; atropine, propylthiouracil and growth hormone products): may distort the diagnostic test; growth hormone products are stopped at least a week beforehandMacrilen (macimorelin) granules for oral solution, US prescribing information, section 7. DailyMed version 3, effective February 18, 2026, read September 30, 2026.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

PubMed

• insulin: in 52 insulin-treated people with type 2 diabetes, 14 days of the complex cut insulin requirements by 54% to 82% and fasting glucose by 32% to 37%, so insulin doses fall and hypoglycaemia becomes the risk when the two are combinedClemmons DR, et al. "Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose." Growth Horm IGF Res, 2005;15(4):265-74. PMID: 16005252. PubMed

The other hits are a review and a 2022 study of its compatibility with administration equipment for infusion, which is not a drug interaction.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

PubMed

• levosimendan: studied as a combination in a 120-patient randomised trial in acute decompensated heart failure; clinical effectiveness at nine days was better with the combination than with controlJia Z, et al. "Levosimendan and nesiritide as a combination therapy in patients with acute heart failure." Am J Med Sci, 2015;349(5):398-405. PMID: 25853935. PubMed
• milrinone: used together in decompensated heart failure, examined in a 2005 report of concomitant useSmull DL, et al. "Concomitant use of nesiritide and milrinone in decompensated congestive heart failure." Am J Health Syst Pharm, 2005;62(3):291-5. PMID: 15719588. PubMed
• heparin, including heparin-coated catheters: nesiritide is incompatible with unfractionated heparin, and a case report examined loss of effect through a heparin-coated pulmonary artery lineBaroletti SA, et al. "Interaction between nesiritide and a heparin-coated pulmonary artery line during an infusion for decompensated heart failure." Pharmacotherapy, 2004;24(11):1634-7. PMID: 15537565. PubMed

Nesiritide is recombinant B-type natriuretic peptide, the same molecule as the BNP entry, whose record carries the milrinone and heparin-catheter findings too.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

PubMed

• conventional antibiotics such as ceftiofur: sub-inhibitory nisin enhanced ceftiofur's activity against resistant Staphylococcus aureus from bovine mastitis in vitroSánchez-Ceja MG, et al. "Nisin or Chitosan Enhance the Antimicrobial Activity of Ceftiofur Against Antibiotic-Resistant Staphylococcus aureus and Have Antibiofilm Effects." Pathogens, 2025;14(12). PMID: 41471173. PubMed
• lysozyme: the two are analysed as a synergistic pair against Listeria biofilms, the combination used in food preservationPolegodage DSR, et al. "The "One-Two Punch": a conceptual analysis of nisin and lysozyme synergy against Listeria monocytogenes biofilms and their dependence on environmental factors." J Appl Microbiol, 2026;137(9). PMID: 42642043. PubMed

Nisin's interaction literature is food preservation and laboratory antimicrobial synergy; no drug interaction study in people was found.

No interaction study was found in a PubMed search on 2026-09-30 (3 hits read).

Hits are a rat EEG study, a mouse study of valproate's anticonvulsant effect, and a review; no human interaction study.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, section 7

• drugs that raise the risk of low blood sugar (other diabetes drugs, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues such as octreotide, sulfonamide antibiotics): dose reduction and more frequent glucose monitoring may be neededHumulin N (insulin human) injection, US prescribing information, section 7. DailyMed version 50, effective December 19, 2025, read September 30, 2026.
• drugs that weaken its glucose-lowering effect (atypical antipsychotics, corticosteroids, danazol, diuretics, oestrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics such as albuterol, epinephrine and terbutaline, thyroid hormones): dose increases and more frequent glucose monitoring may be neededHumulin N (insulin human) injection, US prescribing information, section 7. DailyMed version 50, effective December 19, 2025, read September 30, 2026.
• alcohol, beta-blockers, clonidine and lithium salts: may raise or lower the glucose-lowering effect; pentamidine may cause low blood sugar sometimes followed by high blood sugarHumulin N (insulin human) injection, US prescribing information, section 7. DailyMed version 50, effective December 19, 2025, read September 30, 2026.
• beta-blockers, clonidine, guanethidine and reserpine: may blunt or hide the warning signs of low blood sugarHumulin N (insulin human) injection, US prescribing information, section 7. DailyMed version 50, effective December 19, 2025, read September 30, 2026.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

PubMed

• imiquimod (topical): in 16 healthy volunteers, adding topical omiganan enhanced imiquimod-induced inflammatory responses in the skin (a pharmacodynamic interaction)Niemeyer-van der Kolk, T. et al. (2020). Omiganan Enhances Imiquimod-Induced Inflammatory Responses in Skin of Healthy Volunteers. Clin Transl Sci, 13, 573-579. PubMed

The other two hits are an acne review and a study of a different antimicrobial peptide (DP7).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, section 7

• strong CYP3A4 inhibitors: maximum orforglipron dose 9 mg once daily; avoid strong CYP3A4 inhibitors that also inhibit OATP1BEli Lilly. FOUNDAYO (orforglipron) tablets, US prescribing information, section 7. DailyMed version effective July 29, 2026, read September 30, 2026.
• CYP3A4 inducers: avoid strong inducers; with moderate inducers, monitor effectiveness and escalate the dose as neededEli Lilly. FOUNDAYO (orforglipron) tablets, US prescribing information, section 7. DailyMed version effective July 29, 2026, read September 30, 2026.
• simvastatin: do not exceed simvastatin 20 mg once dailyEli Lilly. FOUNDAYO (orforglipron) tablets, US prescribing information, section 7. DailyMed version effective July 29, 2026, read September 30, 2026.
• oral medications: orforglipron delays gastric emptying and may affect their absorptionEli Lilly. FOUNDAYO (orforglipron) tablets, US prescribing information, section 7. DailyMed version effective July 29, 2026, read September 30, 2026.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, precautions (drug interactions)

• prophylactic vasoconstrictors given with caudal block anaesthesia: severe hypertension reported when oxytocin was given three to four hours laterPar Health. PITOCIN (oxytocin injection), US prescribing information, Precautions: Drug Interactions. DailyMed version effective May 5, 2026, read September 30, 2026.
• cyclopropane anaesthesia: may modify oxytocin's cardiovascular effects, producing unexpected hypotension; maternal sinus bradycardia with abnormal atrioventricular rhythms has been notedPar Health. PITOCIN (oxytocin injection), US prescribing information, Precautions: Drug Interactions. DailyMed version effective May 5, 2026, read September 30, 2026.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (2 hits read).

The two hits are in vitro skin-cell studies of peptide combinations, not drug interactions.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

The one hit is a cosmetic microneedle study, not an interaction study.

FDA label, section 7

• drugs that prolong the QT interval: additive QT prolongation; use with caution in anyone at significant riskSignifor (pasireotide) injection, US prescribing information, section 7. DailyMed version 20, effective February 17, 2026, read September 30, 2026.
• cyclosporine: may lower cyclosporine's relative bioavailability; its dose may need adjusting to hold therapeutic levelsSignifor (pasireotide) injection, US prescribing information, section 7. DailyMed version 20, effective February 17, 2026, read September 30, 2026.
• bromocriptine: somatostatin analogues may raise bromocriptine levels; a dose reduction may be neededSignifor (pasireotide) injection, US prescribing information, section 7. DailyMed version 20, effective February 17, 2026, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

The single hit is an in vitro study of MSI-78 combined with voriconazole and amphotericin B; no human interaction study.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (385 hits read).

385 hits, overwhelmingly in vitro synergy testing of polymyxin B with other antibiotics and compounds against resistant Gram-negative bacteria; none of the top results is a human drug interaction study.

PubMed

• L-arginine: acts synergistically with GHRP-2 on growth hormone release in men and women at rest, and the synergy was studied against exerciseWideman L, et al. "Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise." Am J Physiol Regul Integr Comp Physiol, 2000;279(4):R1467-77. PMID: 11004017. PubMed
• TRH and GnRH: given together with GHRP-2 to men with prolonged critical illness to restore suppressed growth hormone, thyroid and gonadal axes at the same timeVan den Berghe G, et al. "The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone." Clin Endocrinol (Oxf), 2002;56(5):655-69. PMID: 12030918. PubMed

Pralmorelin is GHRP-2 under its INN. The GHRP-2 entry is covered by the site's interaction checker (state partial) and keeps that; this record documents the duplicate entry from the same studies.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (201 hits read).

The query returned 201 hits (46 when restricted to humans), mostly physiology of thyrotropin-releasing hormone and studies of how illness or treatment changes the TRH test; none is an interaction study of protirelin as a drug. The closest, in depressed patients (PMID 14751427), found only a non-significant tendency for TSH responses to rise after antidepressant treatment.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

FDA label, section 7 (Table 1)

• antidiabetic agents, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogues (e.g., octreotide), sulfonamide antibiotics: may increase the risk of hypoglycaemia; dose adjustment and more frequent glucose monitoring may be requiredEli Lilly. HUMULIN R (insulin human injection), US prescribing information, section 7, Table 1. DailyMed version effective June 16, 2026, read September 30, 2026.
• atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics, thyroid hormones: may decrease the glucose-lowering effectEli Lilly. HUMULIN R (insulin human injection), US prescribing information, section 7, Table 1. DailyMed version effective June 16, 2026, read September 30, 2026.
• alcohol, beta-blockers, clonidine, lithium salts; pentamidine: may increase or decrease the glucose-lowering effect; pentamidine may cause hypoglycaemia sometimes followed by hyperglycaemiaEli Lilly. HUMULIN R (insulin human injection), US prescribing information, section 7, Table 1. DailyMed version effective June 16, 2026, read September 30, 2026.
• beta-blockers, clonidine, guanethidine, reserpine: may blunt signs and symptoms of hypoglycaemiaEli Lilly. HUMULIN R (insulin human injection), US prescribing information, section 7, Table 1. DailyMed version effective June 16, 2026, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

FDA label, section 7

• oral P-glycoprotein inhibitors: raise relugolix exposure; avoid, or take Orgovyx first and separate the doses by at least 6 hours, monitoring for adverse reactionsOrgovyx (relugolix) tablets, US prescribing information, section 7. DailyMed version 12, effective October 10, 2025, read September 30, 2026.
• combined P-gp and strong CYP3A inducers: lower relugolix exposure and may reduce its effect; avoid, or raise the dose to 240 mg once dailyOrgovyx (relugolix) tablets, US prescribing information, section 7. DailyMed version 12, effective October 10, 2025, read September 30, 2026.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, section 7

• other ITP therapies — corticosteroids, danazol, azathioprine, intravenous immunoglobulin and anti-D immunoglobulin: the label states Nplate may be used with themNplate (romiplostim) for injection, US prescribing information, section 7. DailyMed version 162, effective June 23, 2026, read September 30, 2026.

FDA label: the Mimrylo prescribing information carries no drug interactions section

• no drug: the label carries no drug interactions section and no boxed warningMimrylo (rusfertide) for injection, US prescribing information. DailyMed version 2, effective August 28, 2026, read September 30, 2026.

FDA label, section 7

• anticholinergic drugs: may cause a hyporesponse to stimulation testing; stop them at least 5 half-lives beforehandChiRhoStim (human secretin) for injection, US prescribing information, section 7. DailyMed version 20251008, effective October 8, 2025, read September 30, 2026.
• H2-receptor antagonists and proton pump inhibitors: may cause a hyperresponse of gastrin, falsely suggesting gastrinoma; stop H2 blockers at least 2 days before, and check each PPI's own labelChiRhoStim (human secretin) for injection, US prescribing information, section 7. DailyMed version 20251008, effective October 8, 2025, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

PubMed

• haloperidol: its effects in rats were studied against dopamine-receptor blockade with haloperidol; animal work, not a human interaction studySebentsova EA, et al. "Effects of semax against the background of dopaminergic receptor blockade with haloperidol." Bull Exp Biol Med, 2006;141(2):170-4. PMID: 16984088. PubMed
• D-amphetamine: in rats it enhanced amphetamine-induced dopamine release in the striatum; animal work, not a human interaction studyEremin KO, et al. "[Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice]." Eksp Klin Farmakol, 2004;67(2):8-11. PMID: 15188751. PubMed

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

FDA label, section 7

• glucocorticoid replacement, especially cortisone acetate and prednisone: growth hormone inhibits 11β-HSD-1 and can lower serum cortisol; maintenance or stress doses may need raisingSogroya (somapacitan-beco) injection, US prescribing information, section 7. DailyMed version 8, effective February 25, 2026, read September 30, 2026.
• drugs metabolised by cytochrome P450 enzymes: growth hormone increases CYP450-mediated clearance; monitor carefullySogroya (somapacitan-beco) injection, US prescribing information, section 7. DailyMed version 8, effective February 25, 2026, read September 30, 2026.
• oral oestrogen: may reduce the IGF-1 response; higher doses may be neededSogroya (somapacitan-beco) injection, US prescribing information, section 7. DailyMed version 8, effective February 25, 2026, read September 30, 2026.
• insulin and other glucose-lowering drugs: may reduce insulin sensitivity, particularly at higher doses; diabetes treatment may need adjustingSogroya (somapacitan-beco) injection, US prescribing information, section 7. DailyMed version 8, effective February 25, 2026, read September 30, 2026.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

FDA label, section 7

• glucocorticoid replacement, especially cortisone acetate and prednisone: growth hormone inhibits 11β-HSD-1 and can lower serum cortisol; maintenance or stress doses may need raisingNgenla (somatrogon-ghla) injection, US prescribing information, section 7. DailyMed version 14, effective August 14, 2026, read September 30, 2026.
• drugs metabolised by cytochrome P450 enzymes: growth hormone increases CYP450-mediated clearance; monitor carefullyNgenla (somatrogon-ghla) injection, US prescribing information, section 7. DailyMed version 14, effective August 14, 2026, read September 30, 2026.
• oral oestrogen: may reduce the IGF-1 response; higher doses may be neededNgenla (somatrogon-ghla) injection, US prescribing information, section 7. DailyMed version 14, effective August 14, 2026, read September 30, 2026.
• insulin and other glucose-lowering drugs: may reduce insulin sensitivity, particularly at higher doses; diabetes treatment may need adjustingNgenla (somatrogon-ghla) injection, US prescribing information, section 7. DailyMed version 14, effective August 14, 2026, read September 30, 2026.
• supraphysiologic glucocorticoid treatment: may blunt the growth-promoting effect in children; adjust replacement dosing carefullyNgenla (somatrogon-ghla) injection, US prescribing information, section 7. DailyMed version 14, effective August 14, 2026, read September 30, 2026.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (2 hits read).

2 hits, both animal or cell studies of elamipretide combined with another agent, not interaction studies in people.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

PubMed

• NPY2R agonists (BI 1820237): combined with a long-acting NPY2R agonist, it produced synergistic weight loss in animal models; a combination-efficacy finding from animals, not a safety interactionAugustin R, et al. "Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide." Mol Metab, 2025;99:102205. PMID: 40619099. PubMed

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

PubMed

• midazolam and other CYP3A4 substrates: in 17 men, one dose raised midazolam exposure (AUC) by 64% and seven days of dosing by 93%, consistent with tabimorelin inhibiting CYP3A4; drugs cleared by that enzyme would be expected to accumulateZdravkovic M, et al. "A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate." Eur J Clin Pharmacol, 2003;58(10):683-8. PMID: 12610745. PubMed

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

PubMed

• lisinopril, warfarin, simvastatin, digoxin and an ethinylestradiol-levonorgestrel contraceptive: five clinical pharmacology studies in healthy volunteers measured how its slowing of gastric emptying changed these oral drugs' absorption; the effect on simvastatin was the most pronouncedBogman K, et al. "Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials." Clin Pharmacokinet, 2019;58(9):1205-1214. PMID: 30968335. PubMed

Development of taspoglutide stopped; no label exists.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

FDA label, section 7

• oral medicines generally: teduglutide may increase their absorption; monitor drugs needing titration or with a narrow therapeutic index, which may need a dose reductionGattex (teduglutide) for injection, US prescribing information, section 7. DailyMed version 20, effective September 5, 2025, read September 30, 2026.
• benzodiazepines: altered mental status was seen in adults taking both in the clinical studiesGattex (teduglutide) for injection, US prescribing information, section 7. DailyMed version 20, effective September 5, 2025, read September 30, 2026.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

PubMed

• octreotide: studied as a combination in portal hypertension, where the two vasoactive drugs were given together; the evidence is a rat haemodynamic study, not a human interaction trialChan CC, et al. "Haemodynamic responses to a combination of terlipressin and octreotide in portal hypertensive rats." Scand J Gastroenterol. 1997;32(11):1159-63. PMID: 9354212. PubMed

The Terlivaz label has no drug interactions section; its boxed warning concerns serious or fatal respiratory failure. The 11 query hits are mostly animal physiology and case reports, and the one carried here is explicitly an animal study.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

PubMed

• itraconazole and other strong CYP3A4 inhibitors: 28 volunteers took a single 2 mg dose, 14 of them after itraconazole 400 mg then 200 mg daily, to measure how the CYP3A4 inhibitor changed exposure to tesofensine, which the study treats as a CYP3A4 substrate with a long half-lifeLehr T, et al. "Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole." Clin Pharmacokinet, 2010;49(1):53-66. PMID: 20000889. PubMed

The other hits are pharmacokinetic modelling papers and a rat appetite study.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

The single hit is a mouse toxicology study of thymus and spleen morphology after combined exposure to a carcinogen, not a drug interaction.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

PubMed

• interferon alfa-2a and interleukin-2: given in sequence with both to 17 patients with metastatic renal cell cancer; no objective responses, toxicity driven mainly by interleukin-2, and the authors advised against the combinationDi Lauro L, et al. "Sequential subcutaneous thymopentin, interferon alpha-2a and interleukin-2 in metastatic renal cell cancer." Tumori, 1995;81(1):42-4. PMID: 7754540. PubMed

Most of the nine hits are false matches on the abbreviation TP (triptolide, testosterone propionate, theophylline).

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

No interaction study was found in a PubMed search on 2026-09-30 (6 hits read).

The six hits are animal and in vitro studies of vascular and airway responses; no interaction study in people.

Pairs for this compound are rated in the Interaction Checker, with the evidence behind each rating.

FDA label, section 7 (which states that no interaction studies were done)

• any drug: the label records that no drug interaction studies have been conducted for the oral capsulesVancocin (vancomycin hydrochloride) capsules, US prescribing information, section 7. DailyMed version 12, effective December 22, 2025, read September 30, 2026.

Oral vancomycin acts in the gut and is minimally absorbed; the intravenous product is a separate label with its own warnings.

FDA label, section 7

• catecholamines: additive effect on blood pressure and other haemodynamic parameters; monitor and adjust the vasopressin dosePar Health. VASOSTRICT (vasopressin) injection, US prescribing information, section 7. DailyMed version of May 20, 2026, read September 30, 2026.
• indomethacin: may prolong vasopressin's effect on cardiac index and systemic vascular resistancePar Health. VASOSTRICT (vasopressin) injection, US prescribing information, section 7. DailyMed version of May 20, 2026, read September 30, 2026.
• ganglionic blocking agents: may increase the pressor responsePar Health. VASOSTRICT (vasopressin) injection, US prescribing information, section 7. DailyMed version of May 20, 2026, read September 30, 2026.
• drugs that cause SIADH: may increase the pressor responsePar Health. VASOSTRICT (vasopressin) injection, US prescribing information, section 7. DailyMed version of May 20, 2026, read September 30, 2026.
• drugs that cause diabetes insipidus: may decrease the pressor responsePar Health. VASOSTRICT (vasopressin) injection, US prescribing information, section 7. DailyMed version of May 20, 2026, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

Not yet reviewed. Until it is, treat its interactions as unknown, not as absent.

No interaction study was found in a PubMed search on 2026-09-30 (91 hits read).

The hits are laboratory studies of VIP's physiology alongside other mediators (histamine, carbachol, retinoic acid); none is a drug interaction study of aviptadil in people.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

No interaction study was found in a PubMed search on 2026-09-30 (1 hit read).

1 hit, a laboratory study combining a phosphatase inhibitor with BMN-111 to enhance bone growth in a model; not an interaction study in people.

FDA label, section 7 (no formal pharmacokinetic interaction studies were performed)

• intrathecal opiates: the combination has not been studied in placebo-controlled trials and the label does not recommend itPrialt (ziconotide acetate) injection, US prescribing information, section 7. DailyMed version 4, effective September 15, 2026, read September 30, 2026.
• CNS depressants — antiepileptics, neuroleptics, sedatives: may raise the incidence of dizziness, confusion and depressed consciousnessPrialt (ziconotide acetate) injection, US prescribing information, section 7. DailyMed version 4, effective September 15, 2026, read September 30, 2026.
• diuretics: named with the above as raising the risk of depressed levels of consciousnessPrialt (ziconotide acetate) injection, US prescribing information, section 7. DailyMed version 4, effective September 15, 2026, read September 30, 2026.

No interaction study was found in a PubMed search on 2026-09-30 (0 hits read).

0 hits. The label carries no interactions section; its boxed warning is about serious meningococcal infections, a risk of complement inhibition rather than an interaction.